XOMA Royalty (XOMA) said Tuesday it has acquired a 50% economic interest in all future milestones and royalties associated with more than 60 early-stage programs under Twist Bioscience's (TWST) biopharma business for an upfront payment of $15 million.
The deal brings XOMA's portfolio to over 100 assets ranging from commercial therapeutics to pre-clinical programs, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments